UCLA Campus    |   UCLA Health    |   School of Medicine Translate:
UCLA Health It Begins With U

Francisco Durazo, MD


Francisco Antonio Durazo, MD

UCLA Physician Francisco Antonio  Durazo, MD specializes in Digestive Diseases.
Digestive Diseases
Language Spoken
English, Spanish, German
Hospital Affiliation
Ronald Reagan UCLA Medical Center
State License Number
(310) 794-7788 Information and referral
(310) 794-5970
Voted Best Doctor
Voted Super Doctor

Pfleger Liver Institute
200 Medical Plaza, Suite 214
Los Angeles, CA 90095

Transplant Hepatology, American Board of Internal Medicine, 2006
Internal Medicine, American Board of Internal Medicine, 1989
Internal Medicine/Gastroenterology, USC University Hospital, 1990 - 1992
Internal Medicine, USC University Hospital, 1989 - 1990
Internal Medicine, USC University Hospital, 1987 - 1989
Internal Medicine, USC University Hospital, 1986 - 1987
MD, Universidad Autonoma del Estado de Mexico, 1981
Biliary, Endoscopic Retrograde Cholangiopancreatography (ERCP), Hepatology, Liver Biopsy, Pancreatobiliary Disease
Research Interest
Hepatocellular carcinoma, Nonalcoholic Fatty Liver Disease, Liver transplantatioin, Biliary diseases
Additional Information


  • Associate CLinical Professor of Medicine and Surgery, University of California, Los Angeles
  • Attending Physician in Hepatology and Transplant Hepatology, Department of Internal Medicine, Division of Gastroenterology and Liver Diseases, Dumont UCLA Liver Transplant Center, University of California, Los Angeles


  • Post-Graduate Internship: American British Cowdray Hospital, México City, México, Nov. 1979 - Oct. 1980
  • Medical School: State of México University, México City, México, 1975-1981
  • College: Colegio Vista Hermosa, México City, México, 1969-1972
    Degree: Chemistry and Biology

Mundo F., Durazo F. Spontaneous Rupture of an Intra-abdominal Neuroblastoma Manifested as an Acute Abdomen. Annals of the American British Cowdray Hospital. September 1980.
Durazo F., Valenzuela JE. Effect of a Single and Repeated Doses of Metoclopramide on Mechanisms of Gastroesophageal Reflux. American Journal of Gastroenterology Oct 93: 88;10;1657-1662.
Durazo F. Evaluation of Mild Abnormalities of Liver enzymes. "The Pulse" (Newsletter of the Mullikin Medical Center), September 1994.
Durazo F. Treatment of Helicobacter pylori Infection. "The Pulse" (Newsletter of the Mullikin Medical Center), December 1995.
Durazo F. Clinical Usefulness of the Carcinoembrionic Antigen. "The Pulse" (Newsletter of the Mullikin Medical Center), October 1996.
Cosenza C, Durazo F, Stain S, Jabour N, Selby R. Management of Recurrent Pyogenic Cholangitis. American Surgeon, in press, 1999.
Han S, Martin P, Edelstein M, Saab S, Hu R, Kunder G, Holt C, Durazo F, Goldstein L, Farmer D, Ghobrial R, Busuttil R. Conversion from Intravenous to Intramuscular Hepatitis B Immune Globulin in Combination with Lamivudine is Safe and Cost-Effective in Patients Receiving Long-Term Prophylaxis to Prevent Hepatitis B Recurrence Post-Liver Transplant. Liver Transplantation 2003 9(2):182-7.
Saab S, Hu R, Ibrahim AB, Goldstein LI, Kunder G, Durazo F, Han S, Yersiz H, Ghobrial RM, Farmer DG, Busuttil RW, Lassman C. Discordance between ALT values and fibrosis in liver transplant recipients treated with ribavirin for recurrent hepatitis C. Am J Transplant. 2003 Mar;3(3):328-33.
Farmer DG, Anselmo DM, Ghobrial RM, Yersiz H, McDiarmid SV, Cao C, Weaver M, Figueroa J, Khan K, Vargas J, Saab S, Han S, Durazo F, Goldstein LI, Holt C, Busuttil RW. Liver transplantation for fulminant hepatic failure: experience with more than 200 patients over a 17-year period. Ann Surg. 2003 May;237(5):666-75; discussion 675-6.
Saab S, DeRosa V, Nieto J, Durazo F, Han S, Roth B. Cost and clinical outcomes of primary prophylaxis of variceal bleeding in patients with hepatic cirrhosis: a decision analytic model. American Journal of Gastroenterology 2003: 98(4):763-70.
Saab S, Wang V, Ibrahim AB, Durazo F, Han S, Farmer DG, Yersiz H, Morrissey M, Goldstein LI, Ghobrial RM, Busuttil RW. MELD score predicts 1-year patient survival post-orthotopic liver transplantation. Liver Transpl. 2003 May;9(5):473-6.
Saab S, Ly David, Nieto J, Kanwal F, Lu D, Raman S, Amado R, Nuesse B, Durazo F, Han S, Farmer D, Ghobrial R, Yersiz, Chen P, Schwegel K, Goldstein L, Tong M, Busuttil R. Hepatocellular Carcinoma Screening in Patients Waiting for Liver Transplantation: A Decision Analytic Model. Liver Transplantation 2003,9;7:672-681.
Saab S, Ghobrial RM, Ibrahim AB, Kunder G, Durazo F, Han S, Farmer DG, Yersiz H, Goldstein LI, Busuttil RW. Hepatitis C Positive Grafts may Be Used in Orthotopic Liver Transplantation: A Matched Analysis. Am J Transplant 3(9):1167-1172, 2003.
Saab S, Chang AJ, Comulada S, Geevarghese S, Anselmo RDM, Durazo F, Han S, Farmer DG, Yersiz H, Goldstein LI, Ghobrial, RM, Busuttil RW. Outcomes of Hepatitis C- and Hepatitis B Core Antibody- Positive Grafts in Orthotopic Liver Transplantation. Liver Transplantation 2003, 9: 1053-1061.
Kanwal F, Chen D, Ting L, Gornbein J, Saab S, Durazo F, Yersiz H, Farmer D, Ghobrial RM, Busuttil RW, Han S. A model to predict the development of mental status changes of unclear cause after liver transplantation. Liver Transpl. 2003 Dec;9(12):1312-9.
Durazo F, Lassman C, Han S, Saab S, Lee N, Kawano M, Saggi B, Gordon S, Farmer D, Yersiz H, Goldstein L, Ghobrial RM, Busuttil RW. Fulminant Liver Failure Due to Usnic Acid for Weight Loss. American Journal of Gastroenterology, 2004 May;99(5):950-2. Saab S, Kalmaz D, Gajjar N, Hiatt J, Durazo F, Han S, Farmer D, Ghobrial RM, Yersiz H, Golstein L, Lassman C, Busuttil RW. Outcomes of Acute Rejection After Interferon Therapy in Liver Transplant Recipients. Liver Transplantation 2004;10:859-867. Shimoda M, Ghobrial RM, Carmody IC, Anselmo DM, Farmer DG, Yersiz H, Chen P, Dawson S, Durazo F, Han S, Goldstein LI, Saab S, Hiatt J, Busuttil RW. Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C. Liver Transpl. 2004 Dec;10(12):1478-86.
Neff GW, Reddy RK, Durazo F, Meyer D, Marrero R, Kaplowitz N. Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. J Hepatol. 2004 Dec;41(6):1062-4.
Saab S, Ibrahim AB, Shpaner A, Younossi ZM, Lee C, Durazo F, Han S, Esrason K, Wu V, Hiatt J, Farmer DG, Ghobrial RM, Holt C, Yersiz H, Goldstein LI, Tong MJ, Busuttil RW. MELD fails to measure quality of life in liver transplant candidates. Liver Transpl 2005;11:218-223. Lu DS, Yu NC, Raman SS, Lassman C, Tong MJ, Britten C, Durazo F, Saab S, Han S, Finn R, Hiatt JR, Busuttil RW. Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma as a Bridge to Liver Transplantation. Hepatology 2005;41:1130-1137.
Busuttil RW, Farmer DG, Yersiz H, Hiatt JR, McDiarmid SV, Goldstein LI, Saab S, Han S, Durazo F, Weaver M, Cao C, Chen T, Lipshutz GS, Holt C, Gordon S, Gornbein J, Amersi F, Ghobrial RM. Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. Ann Surg. 2005 Jun;241(6):905-16; discussion 916-8.
Saab S, Niho H, Comulada S, Hiatt J, Durazo F, Han S, Farmer D, Holt C, Yersiz H, Goldstein L, Ghobrial RM, Busuttil RW. Mortality predictors in liver transplant recipients with recurrent hepatitis C cirrhosis. Liver International 2005: 25: 940-945.
Saab S, Landaverde C, Ibrahim AB, Durazo F, Han S, Yersiz H, Farmer D, Ghobrial RM, Goldstein L, Tong M, Busuttil R. The MELD score in advanced liver disease: Association with clinical portal hypertension and mortality. Experimental and Clinical Transplantation 2006, 1: 395-399.
Saab S, Shpaner A, Zhao Y, Brito I, Durazo F, Han S, Farmer D, Ghobrial RM, Yersiz H, Goldstein L, Tong M, Busuttil RW. Prevalence and risk factors for Diabetes Mellitus in moderate term survivors of liver transplantation. American Journal of Transplantation 2006;6:1890-1895.
Cameron AM, Ghobrial RM, Hiatt JR, Carmody JC, Gordon SA, Farmer DG, Yersiz H, Zimmerman MA, Durazo F, Han S, Saab S, Gornbein J, Busuttil RW. Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann Surg. 2006 Oct;244(4):563-71.
Spiegel B, Bolus R, Han S, Tong M, Esrailian E, Talley J, Tran T, Smith J, Karsan H, Durazo F, Bacon B, Martin P, Younossi Z, Ong SH, Kanwal F. Development and validation of a disease-targeted health-related quality of life (HRQOL) instrument in chronic hepatitis B infection: The HBQOL V1.0. Hepatology 2007;46:113-121.
Saab S, Oh MK, Ibrahim AB, Durazo F, Han S, Yersiz H, Farmer D, Ghobrial RM, Goldstein L, Tong MJ, Busuttil RW. Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C. Liver Transpl. 2007 Jul;13(7):1032-8.
Saab S, Wiese C, Ibrahim AB, Peralta L, Durazo F, Han S, Yersiz H, Farmer D, Ghobrial RM, Goldstein L, Tong M, Busuttil R. Employment and quality of life in liver transplant recipients. Liver transplantation 2007;13:1330-38.
Yan E, Durazo F, Tong MJ, Hong K. Nonalcoholic fatty liver disease: Pathogenesis, identification, progression, and management. Nutr Rev. 2007 Aug;65(8 Pt 1):376-84.
Durazo F, Yan E, Tong MJ. Nonalcoholic fatty liver disease: Identification and treatment. Family Practice Recertification 2007 September; 29(9):1-9.
Durazo F, Blatt LB, Corey WG, Lin JH, Han S, Saab S, Busuttil RW, Tong MJ. A Comparison of des-gamma carboxyprothrombin, alphafetoprotein and AFP-L3% in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. Journal of Gastroenterology and Hepatology, 2008 Apr; 19:
Tabibian JH, Lassman CR, Margolis DJ, Landaverde C, Busuttil RW, Durazo F. Intraductal oncocytic papillary neoplasm of the liver: Case and review of a rare variant. Annals of Hepatology 2008. In press.
Durazo F, Asham E, Tabibian J, Han S, Saab S, Goldstein L, Tong M, Busuttil R. Endoscopic management of post-liver transplant anastomotic strictures. In progress.

Back to top
Referring a Patient to UCLA
Our staff will assist you in selecting the appropriate UCLA clinical department for your patient.

Find out how to refer a patient
Francisco Durazo, click here to update your profile.